Navigation Links
Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy
Date:1/24/2013

ATLANTA, Jan. 24, 2013 /PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that The University of Texas MD Anderson Cancer Center (Houston, Texas) has signed an agreement to join a research group to advance the development of an innovative image-guided treatment technology for cancer care. The technology merges radiation therapy and magnetic resonance imaging (MRI) technology in a single system. MD Anderson is the second member of the research consortium, which will comprise leading radiation oncology centers and clinicians, and already includes the University Medical Center Utrecht (the Netherlands).

Uniting state-of-the-art MRI with a cutting edge radiation therapy system – thus creating an MRI-guided radiation therapy system – will provide physicians with exceptional images of a patient's soft tissues and tumor during radiation therapy. This breakthrough innovation also aims to enable clinicians to adapt treatment delivery in real time for the most precise cancer treatments possible.

"The special capabilities of the MRI-guided radiation therapy system – MR-based soft tissue imaging performed simultaneously with treatment delivery – could revolutionize cancer care," says Jay Hoey , Executive Vice President, Elekta North America . "Patients are the ultimate winners, because MR imaging will help put the therapeutic radiation right on target, with the potential to avoid exposure to normal tissues. My colleagues at Elekta, Philips and University Medical Center Utrecht are thrilled to welcome MD Anderson to the research consortium, which will profit immensely from this center's high-caliber medical, technological and patient care expertise."

"MRI is the gold standard modality for imaging soft tissues, and MR imaging of the cance
'/>"/>

SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
2. Elekta President and CEO Tomas Puusepp Pledges Support in Addressing Global Cancer Challenge at World Cancer Leaders Summit in Montreal
3. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
4. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
5. Find New Cancer Treatments at cureLauncher
6. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
7. New Shared Synthetic Replikin Cancer Vaccines
8. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
9. Genetic basis of high-risk childhood cancer points to possible new drug treatment strategy
10. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
11. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
... of Chemistry Dunwei Wang has received a career award ... energy technology research and expand the community outreach programs ... on developing novel technologies for clean energy applications, has ... a flexible webbing of nano-scale wires that has shown ...
... N.C., Jan. 10, 2011 Takeda Pharmaceutical Company ... they have entered into an exclusive, worldwide licensing ... for the risk of Alzheimer,s disease in high-risk ... study pioglitazone in connection with the TOMM40 biomarker ...
... 10, 2011 Enobia Pharma Inc., today announced that ... ENB-0040, a bone targeted enzyme replacement therapy being investigated ... bone disorder. The results were presented by Robert Heft, ... the 29th Annual J.P. Morgan Healthcare Conference in San ...
Cached Biology Technology:Developer of 'nanonets' snares National Science Foundation Career Award 2Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... accurate method yet for predicting the doses of radiation ... module, Columbus, attached to the ISS this week. ... radiation particles passing through spacecraft walls and human bodies. ... the radiation doses received by astronauts on future voyages ...
... university Karolinska Institutet shows that the brains serotonin system ... the study think that they have found one of ... common in women than in men. Serotonin ... development and treatment of depression and chronic anxiety, conditions ...
... Valentines Day snuggle can prematurely end a love affair, as ... significantly increases a smokers risk of an early heart attack. ... of the population has a gene defect that delivers a ... heavy smokers with this common gene variant experienced a heart ...
Cached Biology News:Predicting the radiation risk to ESA's astronauts 2Predicting the radiation risk to ESA's astronauts 3Cigarette after Valentine snuggle deadlier for some 2Cigarette after Valentine snuggle deadlier for some 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Buffer III is intented ... of PBMCs (or lysed ... for intracellular kinases and ... Applications: Intracellular Staining ...
Biology Products: